Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enasidenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH2 known ✓ | P48735 | 13/20 | 0.87 |
| ▸ | IDH1 | O75874 | 13/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.87 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.87 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.87 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.87 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.87 |
| ▸ | KDR | P35968 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enasidenib SCHEMBL29360046 | 0.93 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL15102202 | 0.93 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774522 | 0.93 | IDH2 (0.75) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774523 | 0.90 | IDH2 (0.77) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102425 | 0.90 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL15102444 | 0.90 | IDH1 (0.93) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL29773080 | 0.89 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL16448052 | 0.89 | IDH2 (1.00) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| SCHEMBL18774538 | 0.88 | IDH2 (0.68) | IDH2IDH1ABCB11ADORA3CHRM1 | |
| Enasidenib SCHEMBL30885350 | 0.88 | IDH2 (0.82) | IDH2IDH1ABCB11ADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3932408-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3566706-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-10730854-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-3566706-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10201543-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180370951-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2018-12-27 | — | — | US | disclosed |
| US-10105369-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-10093654-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20180125850-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2018-05-10 | — | — | US | disclosed |
| US-9889137-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-20180028539-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2018-02-01 | — | — | US | disclosed |
| US-20170305885-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-10-26 | — | — | US | disclosed |
| US-20170266193-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-09-21 | — | — | US | disclosed |
| US-9738625-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160194305-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10201543-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BAK1 | IDH2 168/4885IDH1 137/4885ABCB11 3961/4885 |
| US-20170266193-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | NFATC1, BCL6, MCTS1 | IDH2 22/4885IDH1 14/4885ABCB11 4471/4885 |
| US-20180125850-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | NFATC1, BCL6, MCTS1 | IDH2 22/4885IDH1 14/4885ABCB11 4471/4885 |
| US-10093654-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | IDH2 123/4885IDH1 238/4885ABCB11 3369/4885 |
| US-20170305885-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | IDH2 123/4885IDH1 238/4885ABCB11 3369/4885 |
| US-10105369-B2 | Therapeutically active compounds and their methods of use | NFATC1, BCL6, MCTS1 | IDH2 22/4885IDH1 14/4885ABCB11 4471/4885 |
| US-20180028539-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BAK1 | IDH2 168/4885IDH1 137/4885ABCB11 3961/4885 |
| US-20180370951-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, DLD | IDH2 73/4885IDH1 124/4885ABCB11 2959/4885 |
| US-20160194305-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | IDH2, IDH1, IDH3A | IDH2 1/4885IDH1 2/4885ABCB11 1389/4885 |
| US-10730854-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, DLD | IDH2 73/4885IDH1 124/4885ABCB11 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.